Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

Vivos Therapeutics, headquartered in Colorado, went public via a merger with a special purpose acquisition company in 2020. The company was founded by a team of dentists and medical professionals focused on creating non-invasive sleep apnea treatments. Its flagship product, the Vivos System, uses a custom-fit oral appliance to guide jaw and airway development over time, distinguishing it from daily-use CPAP devices. The firm's strategy centers on commercializing and expanding the adoption of its dental-sleep medicine approach, partnering with dental practitioners and sleep clinics. It has secured FDA clearance for its appliance under specific indications. Vivos has reported treating over 30,000 patients globally as of 2024. Revenue is derived from sales of the appliances and training programs for clinicians. The company competes in the broader sleep apnea market, valued at billions of dollars, alongside ResMed, Philips, and SomnoMed. As a public company traded on the Nasdaq (ticker: VVOS), Vivos has disclosed in SEC filings a small corporate staff and a board of directors including CEO Kirk Huntsman. The company reported revenues of approximately $6.5 million for fiscal year 2023, with net losses reflecting ongoing investment in sales, marketing, and clinical studies. No additional offices or philanthropic arms are publicly identified. Vivos' structural differentiator lies in its treatment approach: it aims to modify the airway structure over time, potentially eliminating the need for lifelong nightly CPAP use. This places it in a niche between dental appliances and surgical intervention, backed by published clinical data. The firm's public-company status provides transparency into financials and governance not typical of private family offices.